{"Exaggerate": "The claim may exaggerate the increase in medicine prices under the new Pakistan government by presenting a single example without providing sufficient evidence or data to support the generalization.", "Lack enough support": "The claim lacks enough support as it only provides one example of a price increase without presenting a comprehensive analysis or comparison of medicine prices under the new government.", "Problematic assumption": "The claim assumes that the increase in medicine prices is solely attributed to the new government without considering other factors or alternative explanations.", "Understate": "The claim may understate the actual increase in medicine prices by focusing on a single product (Cefaclor) and not providing a broader analysis of the overall medicine market.", "Contradict fact": "The claim contradicts the information provided by Pakistan's Drug Regulatory Authority, which states that medicine prices have only slightly risen over the last year and are not solely influenced by the change in government.", "Exist alternative explanation": "The claim does not consider alternative explanations for the increase in medicine prices, such as inflation, changes in international market prices, or other economic factors."}